Britain and America have forged a major trade agreement that will keep no duties on British pharmaceutical exports going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the NHS. This move guarantees that duties on these crucial exports will be held at nothing for a duration of 36 months.
This deal comes after recent warnings to dramatically increase import taxes on branded pharmaceutical imports, with increases discussed up to double the cost.
"This deal with the UK reinforces the international landscape for innovative medicines and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Trade Importance
Pharmaceuticals represent one of the UK's most significant exports to the America, which is clearly the primary market for leading companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to September, the UK exported pharmaceutical products totaling £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This deal secures employment, stimulates funding and paves the way for the UK to emerge as a international leader for life sciences," a minister remarked.
Key British Pledges
The agreement involves several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Last year, refunds topped twenty percent.
Industry Background
The deal comes amid a ongoing row between the drug companies and the ministers over drug pricing and regulatory access.
The disagreement were intensified by assertions that American patients were charged several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward American operations.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the previous ten-year period.
